Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2017-06-19 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text includes a description of an event (patent grant) and references an attached press release. The document length is 2987 characters, which is relatively short and mainly serves as an announcement rather than a detailed report. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, nor is it a transcript or management discussion. It is a regulatory filing to announce a material event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-12 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content specifically announces the hiring and appointment of a new General Counsel and Secretary to the Board of Directors. This is a clear announcement of a change in senior management. There are no financial statements or detailed financial data present, and the document is relatively short (2841 characters). The primary focus is on management change, not on financial results or other report types. Therefore, the appropriate classification is Board/Management Information (MANG).
2017-06-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.